Last updated: February 15, 2026
Overview
Altretamine, marketed under brand names such as Hexalen, is an alkylating agent approved by the FDA in 1982 for the treatment of refractory ovarian cancer. Its market presence remains limited due to its niche application, side effect profile, and competition from newer therapies. The drug's patent expired in the early 2000s, leading to generic manufacturing. Its commercial impact depends on use in specific oncology indications, primarily ovarian cancer, and emerging therapeutic alternatives.
Market Size and Demand
The ovarian cancer treatment market was valued at approximately $1.2 billion globally in 2022, with a compound annual growth rate (CAGR) forecasted around 4.5% through 2028 (ResearchAndMarkets, 2022). Altretamine's share remains minimal due to lack of new indications, with estimates placing its global revenue below $10 million annually, primarily from generic sales in specialized markets.
Market Drivers
- Existing Indication: Ovarian cancer refractory cases, where few options exist.
- Limited Competition: Few alkylating agents are used today for ovarian cancer, and altretamine's niche status sustains some demand.
- Regulatory Status: Approved but not recently reevaluated, with no new formulations or indications approved.
Market Constraints
- Safety Profile: Side effects include neurotoxicity, hematologic toxicity, and gastrointestinal disturbances, reducing appeal.
- Efficacy: Marginal compared to newer agents, such as PARP inhibitors.
- Emerging Therapies: PARP inhibitors (e.g., olaparib) and targeted treatments have eclipsed altretamine, limiting growth.
- Generic Competition: No patent protection since early 2000s, leading to pricing pressure and limited R&D investment.
Financial Trajectory
- Current Revenue: Estimated below $10 million per year, primarily from select markets.
- Pricing: Low, reflecting generic status and limited use cases.
- Profitability: Marginal; manufacturing costs are low, but market volume is constrained.
- Forecast: Demand likely to decline further due to the emergence of superior therapies and the drug’s side effect profile. Little to no influx of investment or R&D activity is anticipated for new indications.
Potential Market Trends
- The fragmentary use of altretamine in combination therapies may sustain minimal demand but is unlikely to drive significant revenue.
- Off-label use remains negligible due to safety concerns and efficacy limitations.
- Clinical interest in repurposing altretamine appears limited, with no recent published trials or investigational activity.
Competitive Landscape
| Drug Class |
Examples |
Status |
Market Share (Est.) |
Remarks |
| Alkylating agents |
Altretamine, cyclophosphamide |
Declining usage |
Minor |
Limited due to toxicity and efficacy issues |
| PARP inhibitors |
Olaparib, niraparib |
Growing |
Major |
Replaces older agents for ovarian cancer |
| Targeted therapies |
Bevacizumab, pembrolizumab |
Increasing |
Significant |
Focus shifts away from alkylating agents |
Conclusion
Altretamine's market remains confined within a small, historic niche. Its revenue trajectory is declining due to competition from newer, targeted therapies offering better safety and efficacy profiles. The likelihood of resurgence or rapid growth is negligible absent new indications or formulations. Industry focus continues toward molecular targeted treatments rather than classic alkylating agents like altretamine.
Key Takeaways
- Altretamine's global annual revenue hovers below $10 million, with no recent R&D activity.
- Its primary use is in refractory ovarian cancer, an area increasingly served by PARP inhibitors.
- Market growth prospects are minimal, constrained by safety concerns and competition.
- Patent expiration in the early 2000s led to generic manufacturing, limiting pricing power.
- Future demand is unlikely to recover without significant new indications or formulations.
FAQs
1. What is the current clinical role of altretamine?
It is used in refractory ovarian cancer, primarily in cases resistant to standard chemotherapy. Its role is limited, with no recent clinical guideline endorsements.
2. Are there any ongoing trials or investigational uses for altretamine?
Current clinical trial activity is negligible. Most research focuses on newer agents with better safety profiles.
3. How does altretamine compare to competing therapies?
It offers limited efficacy and has significant toxicity concerns, leading to its displacement by targeted therapies like PARP inhibitors.
4. Can altretamine regain market relevance?
Unlikely without new indications or formulations. The trend favors targeted, precision medicines over traditional alkylating agents.
5. What factors influenced the decline in altretamine’s market?
Patent expiry in the early 2000s, safety issues, inferior efficacy, and the advent of newer therapies contribute to its declining relevance.
References
- Research and Markets. "Global Ovarian Cancer Therapeutics Market Report," 2022.
- FDA Drug Approval Records, 1982.
- U.S. Patent Office records, 2000.
